Table 2. Characteristics of surveillance sites included in meta-analysis (n = 21).

Country	Population	Vaccine Schedulea	Catch-up	Percent PCV7 Coverageb		Type of Surveillancec	n Surveillance Yearsd			Average Annual n IPD Isolates Pre-PCV7		Percent Meningitis Cases pre-PCV7
				Year 1	Maximum		Pre-PCV7	Post-PCV7		<5 y	≥18 y	<5 y	≥18 y
Australia	Indigenous (NT)	3+PPVa	Y	73	86	P	5	8		20	31	9	0
Australia	Non-indigenous	3+0	Y	89	92	P	3	5		415	831	3	0
Canada	Calgary	3+1	Y	89	94	A	4	7		14	77	19	3
Czech Republic	National	3+1	N	80	80	P	2	1		35	207	N/Ae	N/Ae
Denmark	National	2+1	Y	89	90	P	5	3		91	984	22	6
England and Wales	National	2+1	Y	84	93	P	5f	3		690	4,929	13	2
France	Metropolitan	2+1	N	N/Pb	80	A	2	6		N/Ag	N/Ag	23	N/Ae
Greece	Crete	3+1	Y	60	92	P	5	4		2	3	25	0
Ireland	National	2+1	Y	N/Pb	88	P	4	2		N/Ag	N/Ag	4	0
Israel	National	2+1	Y	85	85	A	5	1		238	N/Ag	11	N/Ae
The Netherlands	National	3+1	N	94	94	P	5f	3		49	596	34	8
New Zealand	National	3+1	Y	88	90	P	5	2		159	341	7	2
Norway	National	2+1	N	94	95	P	4f	4		92	969	N/Ae	5
Scotland	National	2+1	Y	N/Pb	97	P	3	4		86	568	8	1
Switzerland	National	2+1	N	30	80	P	3	3		73	783	8	2
Uruguay	National	2+1	Y	91	91	P	5	2		103	N/Ag	10	N/Ae
USA	Seven sites (ABCs)	3+1	Y	7	93	A	2	9		358	2,796	13	3
USA	Alaska	3+1	Y	20	87	A	5	7		19	76	14	5
USA	Navajo	3+1	Y	80	90	A	5f	10		20	91	4	1
USA	KPNC	3+1	Y	33	81	P	4	4		22	N/Ag	9	N/Ae
USA	Utah	3+1	Y	N/Pb	90	A	3		10	20	N/Ag	21	N/Ae

Australia non-Indigenous does not include data from the State of New South Wales.

^aVaccine schedule  =  Primary + booster.

^bProportion of children receiving the full infant dose by 12 months. N/P (not provided), meaning that immunization coverage not provided for year 1 and/or last year of surveillance data provided, although all included datasets were from sites that indicated they reached ≥70% coverage in the post-PCV period.

^cActive (A), proactive effort to identify all cases in an area; passive (P), reporting of cases by clinicians or laboratories without a systematic approach to capture cases not reported.

^dNumber of surveillance years included in the IPD analysis for children <5 y. Number of surveillance years the same for adult age groups unless otherwise indicated.

^eNot applicable (N/A), age group not included in meningitis analysis. For some sites, some ≥18 y age categories excluded from meningitis analysis (Table 1; Table S1).

^fSite, adult age group (n surveillance years). England and Wales: 18–49 y (4); 50–64 y, and ≥65 y (2). The Netherlands: ≥18 y (2). Norway: ≥18 y (2). USA-Navajo: 50–64 y (4).

^gNot applicable (NA), age group not included in IPD analysis. France and Ireland only included in the meningitis only analysis.

ABCs, Active Bacterial Core Surveillance; KPNC, Kaiser Permanente Northern California; NT, Northern Territory; PPV, pneumococcal polysaccharide vaccine.